Lynparza plus bevacizumab meets primary endpoint in PAOLA-1 trial
The late-stage study called PAOLA-1 evaluated Lynparza plus bevacizumab in the first line maintenance setting in comparison to bevacizumab alone in women with advanced ovarian cancer, irrespective of